Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.57 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.57 |
| ▸ | POLB | P06746 | 1/20 | 0.57 |
| ▸ | GLA | P06280 | 1/20 | 0.57 |
| ▸ | AKR1B1 | P15121 | 1/20 | 0.54 |
| ▸ | HCRTR1 | O43613 | 2/20 | 0.51 |
| ▸ | SGMS2 | Q8NHU3 | 1/20 | 0.51 |
| ▸ | MEN1 | O00255 | 5/20 | 0.50 |
| ▸ | KMT2A | Q03164 | 5/20 | 0.50 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.50 |
| ▸ | PTGDR2 | Q9Y5Y4 | 3/20 | 0.50 |
| ▸ | HTT | P42858 | 1/20 | 0.50 |
| ▸ | MAPT | P10636 | 1/20 | 0.50 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.50 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.50 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.50 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.50 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.50 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.50 |
| ▸ | HPGD | P15428 | 1/20 | 0.50 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19212900 | 0.85 | ALDH1A1 (0.60) | SMN1; SMN2GLAHCRTR1SGMS2MEN1 | |
| SCHEMBL6400854 | 0.83 | HCRTR1 (0.73) | L3MBTL1HCRTR1MEN1KMT2AKDM4E | |
| SCHEMBL14428116 | 0.82 | SGMS2 (0.75) | L3MBTL1SGMS2MEN1KMT2AMAPT | |
| SCHEMBL7105901 | 0.82 | SGMS2 (0.70) | SMN1; SMN2SGMS2MEN1KMT2AKDM4E | |
| SCHEMBL1280991 | 0.81 | POLB (0.64) | L3MBTL1SMN1; SMN2POLBGLAMEN1 | |
| SCHEMBL11202907 | 0.81 | HCRTR1 (0.53) | GLAHCRTR1SGMS2MEN1KMT2A | |
| SCHEMBL15905692 | 0.81 | GAA (0.53) | L3MBTL1GLAHCRTR1SGMS2MEN1 | |
| SCHEMBL4006491 | 0.81 | LMNA (0.64) | L3MBTL1SMN1; SMN2POLBGLAKDM4E | |
| SCHEMBL17372941 | 0.81 | KMT2A (0.75) | L3MBTL1SMN1; SMN2HCRTR1SGMS2MEN1 | |
| SCHEMBL8414408 | 0.80 | L3MBTL1 (0.61) | L3MBTL1SMN1; SMN2POLBGLAAKR1B1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20220411389-A1 | COMPOUNDS AND METHODS FOR TREATING CANCER | MAYO FOUNDATION FOR MEDICAL EDUCATION AND RESEARCH (US) | 2022-12-29 | — | — | US | disclosed |
| US-11325892-B2 | Compounds and methods for treating cancer | MAYO FOUNDATION FOR MEDICAL EDUCATION AND RESEARCH (US) | 2022-05-10 | — | — | US | disclosed |
| US-20190345123-A1 | COMPOUNDS AND METHODS FOR TREATING CANCER | MAYO FOUNDATION FOR MEDICAL EDUCATION AND RESEARCH (US) | 2019-11-14 | — | — | US | disclosed |
| US-10301273-B2 | Compounds and methods for treating cancer | MAYO FOUNDATION FOR MEDICAL EDUCATION AND RESEARCH (US) | 2019-05-28 | — | — | US | disclosed |
| US-20170226073-A1 | COMPOUNDS AND METHODS FOR TREATING CANCER | MAYO FOUNDATION FOR MEDICAL EDUCATION AND RESEARCH (US) | 2017-08-10 | — | — | US | disclosed |
| US-20170226073-A1 | COMPOUNDS AND METHODS FOR TREATING CANCER | MAYO FOUNDATION FOR MEDICAL EDUCATION AND RESEARCH (US) | 2017-08-10 | — | — | US | disclosed |
| US-20070093483-A1 | Use of derivatives of 2, 4-dihydro-[1,2,4] triazole-3-thione as inhibitors of the enzyme myeloperoxidase (mpo) | ASTRAZENECA AB (SE) | 2007-04-26 | — | — | US | disclosed |
| EP-1620410-A1 | USE OF DERIVATIVES OF 2, 4-DIHYDRO- 1,2,4 TRIAZOLE-3-THIONE AS INHIBITORS OF THE ENZYME MYELOPEROXIDASE (MPO) | AstraZeneca AB (SE) | 2006-02-01 | — | — | EP | disclosed |
| WO-2004096781-A1 | USE OF DERIVATIVES OF 2, 4-DIHYDRO-[1,2,4]TRIAZOLE-3-THIONE AS INHIBITORS O FTEH ENZYME MYELOPEROXIDASE (MPO) | ASTRAZENECA AB (SE) | 2004-11-11 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11325892-B2 | Compounds and methods for treating cancer | SCD, CPT1B, CPT1A | L3MBTL1 1974/4885SMN1; SMN2 2189/4885POLB 1484/4885 |
| US-20220411389-A1 | COMPOUNDS AND METHODS FOR TREATING CANCER | SCD, CPT1B, CPT1A | L3MBTL1 1974/4885SMN1; SMN2 2189/4885POLB 1484/4885 |
| US-10301273-B2 | Compounds and methods for treating cancer | SCD, CPT1B, CPT1A | L3MBTL1 1974/4885SMN1; SMN2 2189/4885POLB 1484/4885 |
| US-20170226073-A1 | COMPOUNDS AND METHODS FOR TREATING CANCER | SCD, CPT1B, CPT1A | L3MBTL1 1974/4885SMN1; SMN2 2189/4885POLB 1484/4885 |
| US-20070093483-A1 | Use of derivatives of 2, 4-dihydro-[1,2,4] triazole-3-thione as inhibitors of the enzyme myeloperoxidase (mpo) | MPO, XDH, EPX | L3MBTL1 3772/4885SMN1; SMN2 1917/4885POLB 798/4885 |
| US-20190345123-A1 | COMPOUNDS AND METHODS FOR TREATING CANCER | SCD, CPT1B, CPT1A | L3MBTL1 1974/4885SMN1; SMN2 2189/4885POLB 1484/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.